KR102917499B1 - 백혈병 억제 인자 활성을 억제하기 위한 가용성 폴리펩타이드 및 이의 사용 방법 - Google Patents

백혈병 억제 인자 활성을 억제하기 위한 가용성 폴리펩타이드 및 이의 사용 방법

Info

Publication number
KR102917499B1
KR102917499B1 KR1020217004873A KR20217004873A KR102917499B1 KR 102917499 B1 KR102917499 B1 KR 102917499B1 KR 1020217004873 A KR1020217004873 A KR 1020217004873A KR 20217004873 A KR20217004873 A KR 20217004873A KR 102917499 B1 KR102917499 B1 KR 102917499B1
Authority
KR
South Korea
Prior art keywords
ser
lifr
thr
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217004873A
Other languages
English (en)
Korean (ko)
Other versions
KR20210032493A (ko
Inventor
션 알렉산더 헌터
제니퍼 알. 코크란
Original Assignee
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 filed Critical 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티
Publication of KR20210032493A publication Critical patent/KR20210032493A/ko
Application granted granted Critical
Publication of KR102917499B1 publication Critical patent/KR102917499B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217004873A 2018-07-20 2019-07-19 백혈병 억제 인자 활성을 억제하기 위한 가용성 폴리펩타이드 및 이의 사용 방법 Active KR102917499B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701399P 2018-07-20 2018-07-20
US62/701,399 2018-07-20
PCT/US2019/042648 WO2020018932A1 (en) 2018-07-20 2019-07-19 Soluble polypeptides and methods of using same for inhibiting leukemia inhibitory factor activity

Publications (2)

Publication Number Publication Date
KR20210032493A KR20210032493A (ko) 2021-03-24
KR102917499B1 true KR102917499B1 (ko) 2026-01-26

Family

ID=69164867

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217004873A Active KR102917499B1 (ko) 2018-07-20 2019-07-19 백혈병 억제 인자 활성을 억제하기 위한 가용성 폴리펩타이드 및 이의 사용 방법

Country Status (8)

Country Link
US (1) US12049490B2 (https=)
EP (1) EP3823983A4 (https=)
JP (2) JP7580800B2 (https=)
KR (1) KR102917499B1 (https=)
CN (1) CN112673017A (https=)
AU (1) AU2019305086B2 (https=)
CA (1) CA3106679A1 (https=)
WO (1) WO2020018932A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026006563A1 (en) * 2024-06-27 2026-01-02 Nvasc, Inc. Long-lasting lif proteins and formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2097291A1 (en) * 1990-12-13 1992-06-14 David P. Gearing Leukemia inhibitory factor receptors
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
CA2139504A1 (en) * 1992-07-01 1994-01-20 Nicos A. Nicola Leukaemia inhibitory factor-binding protein
AUPO632897A0 (en) * 1997-04-21 1997-05-15 Walter And Eliza Hall Institute Of Medical Research, The Novel chimeric molecules
EP1878745B1 (en) * 2005-04-22 2011-06-15 Keio University Humanin receptor or humanin-like polypeptide receptor
KR101235820B1 (ko) * 2012-02-17 2013-02-21 한국생명공학연구원 항암 표적치료제제 감수성 예측용 ｓｎｐ
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
WO2018029586A1 (en) * 2016-08-07 2018-02-15 Novartis Ag Mrna-mediated immunization methods

Also Published As

Publication number Publication date
EP3823983A4 (en) 2022-05-18
EP3823983A1 (en) 2021-05-26
CA3106679A1 (en) 2020-01-23
AU2019305086B2 (en) 2024-11-28
KR20210032493A (ko) 2021-03-24
JP2021531002A (ja) 2021-11-18
US20210300992A1 (en) 2021-09-30
WO2020018932A1 (en) 2020-01-23
US12049490B2 (en) 2024-07-30
JP7580800B2 (ja) 2024-11-12
JP2024138287A (ja) 2024-10-08
AU2019305086A1 (en) 2021-02-18
CN112673017A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
US12006361B2 (en) Albumin binding domain fusion proteins
JP2021178823A (ja) 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
CN107074928B (zh) 新型猫促红细胞生成素受体激动剂
KR20170138574A (ko) 항암 융합 폴리펩타이드
JP7821741B2 (ja) 動物用のｉｌ４／ｉｌ１３受容体分子
CN113840831A (zh) 医用ngf拮抗剂
JP2023510871A (ja) Ｉｌ２ムテイン
WO2022032042A1 (en) Il12 receptor synthetic cytokines and methods of use
JP5581214B2 (ja) 改善された結合活性をもつ可溶性ｇｐ１３０変異蛋白質
WO2022032025A1 (en) Ifngr binding synthetic cytokines and methods of use
JP7438975B2 (ja) Ｃｘｃｒ３リガンド
KR102917499B1 (ko) 백혈병 억제 인자 활성을 억제하기 위한 가용성 폴리펩타이드 및 이의 사용 방법
KR102667654B1 (ko) 섬모 신경영양 인자 수용체 리간드-결합제 및 이의 사용 방법
US20230391891A1 (en) Il28a receptor binding synthetic cytokines and methods of use
RU2829812C2 (ru) Антагонисты ngf для медицинского использования
RU2786444C2 (ru) Слитые белки с альбумин-связывающими доменами
CN101878224A (zh) 促红细胞生成素融合蛋白
HK40126456A (en) Albumin binding domain fusion proteins
HK40015886B (en) Albumin binding domain fusion proteins
HK40015886A (en) Albumin binding domain fusion proteins
HK40014589B (zh) 睫状神经营养因子受体配体结合剂及其使用方法
KR20170027795A (ko) 항-사이토카인 항체의 동정을 위한 인간-유래 항-인간 il-20 항체 및 검정

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)